Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Merck Launches NEXPLANON 68 Mg In U.S.

RELATED NEWS
Trade MRK now with 

Merck & Co. (MRK: Quote) said Wednesday that NEXPLANON 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States. NEXPLANON is approved by the FDA for the prevention of pregnancy in women for up to three years.

NEXPLANON must be removed by the end of the third year and may be replaced by a new NEXPLANON, if continued contraceptive protection is desired.

About the size of a matchstick, NEXPLANON is made of a soft, flexible, medical polymer and is inserted just under the skin of a woman's upper arm in a minor surgical in-office procedure.

NEXPLANON is effective, when inserted correctly, with less than 1 pregnancy per 100 women who used NEXPLANON for 1 year. NEXPLANON may be less effective in women who are very overweight and in women who are taking medications that induce liver enzymes. NEXPLANON is a progestin-only contraceptive that does not contain estrogen. NEXPLANON does not depend on daily, weekly, monthly, or quarterly administration. Etonogestrel, the progestin in NEXPLANON, prevents pregnancy in three ways: inhibiting ovulation, thickening of the cervical mucus, and alterations in the endometrium.

Click here to receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After failing to sustain an initial upward move, stocks fluctuated over the course of the trading session on Wednesday before ending the day mixed. The choppy trading came as traders digested upbeat GDP data as well as the Federal Reserve's monetary policy announcement. President Barack Obama took Congress to task in remarks on the economy on Wednesday, accusing Republicans of wasting valuable time by voting on a resolution regarding whether or not to sue him over his use of executive actions. In a surprise move, the Senate voted Tuesday to make changes to an important House highway funding bill, raising questions about whether the legislation will receive final approval before lawmakers leave town for the August recess.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.